文献速递老年综合评估衰弱、肌少症与跌倒老年慢病共病管理

老年癌症患者1年死亡预测:PROFIT研究中G8、SPPB与IF-VIG的表现

Predicting 1-year mortality in older cancer patients: performance of G8, SPPB, and IF-VIG in the PROFIT Study.
PubMed 文献 · J Gerontol A Biol Sci Med Sci · 2026-01-01

PROFIT多中心队列研究纳入229例≥65岁癌症患者,评估G8、SPPB与IF-VIG对1年死亡的预测效能。三种工具均与1年死亡显著相关,SPPB与IF-VIG预后准确性优于G8,优化截断值可提升预测表现。

要点

  • G8、SPPB与IF-VIG均与老年癌症患者1年死亡显著相关。
  • SPPB与IF-VIG的预后准确性优于G8。
  • 优化截断值(G8 12.5、SPPB 8、IF-VIG 0.16)较标准阈值提升预测表现。

核心结论

  • 三种衰弱评估工具均与老年癌症患者1年死亡显著相关。
  • SPPB与IF-VIG在预后准确性上优于G8,可能有助于临床决策。

研究设计与样本

  • 多中心队列研究(PROFIT Study),纳入≥65岁癌症患者229例,平均年龄75.1±6.4岁,68.6%为男性。
  • 患者在肿瘤门诊及急性后期老年肿瘤单元接受评估,随访1年死亡。
  • 采用G8、SPPB与IF-VIG测量衰弱,用ROC曲线及优化截断值分析预测能力,并用协变量校正Cox回归评估关联。

主要发现

  • 229例中146例(63.7%)在1年内死亡。
  • 所有工具均显示预测价值,IF-VIG敏感性最高,SPPB特异性最高。
  • 校正Cox模型显示与1年死亡的关联:G8 HR 1.97(95%CI 1.30-2.99),SPPB HR 2.35(95%CI 1.52-3.64),IF-VIG HR 2.42(95%CI 1.50-3.90)。
  • 优化截断值较标准阈值改善预测表现:G8 12.5 vs 14,SPPB 8 vs 9,IF-VIG 0.16 vs 0.25。

关键数值与推荐

  • G8优化截断值为12.5(标准阈值14)。
  • SPPB优化截断值为8(标准阈值9)。
  • IF-VIG优化截断值为0.16(标准阈值0.25)。

临床怎么用

  • 在老年癌症患者中可用G8、SPPB或IF-VIG评估衰弱以辅助预后判断。
  • 若追求更高预后准确性,可优先考虑SPPB或IF-VIG。
  • 采用本研究报告的优化截断值可能改善预测表现,但需结合临床情境。

局限性

  • 原文摘要未报告局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Frailty is a prognostic determinant in older patients, yet the most effective tools to predict survival remain unclear. This study aimed to assess the predictive performance of different frailty assessment tools for 1-year mortality in the oncogeriatric population. METHODS: A multicenter cohort study (PROFIT Study) involved patients aged ≥65 with cancer, evaluated in oncology clinics and post-acute oncogeriatric units. Frailty was measured using the Geriatric 8 questionnaire (G8), Short Physical Performance Battery (SPPB), and the Frailty Index Indice Frágil-Valoración Integral Geriátrica (IF-VIG). One-year mortality was monitored. Predictive ability was analyzed using receiver operating characteristic curves with optimized cut-offs, and covariate-adjusted Cox regression models were used to evaluate the association between frailty and mortality. RESULTS: Among 229 patients (mean age 75.1 ± 6.4 years; 68.6% male; cancer type: 47.2% lung cancer, 17.9% colorectal, 25.3% other gastrointestinal, 9.6% prostate; tumoral stage IV: 85.2%), 146 (63.7%) died within 1 year. All tools showed predictive value, with IF-VIG demonstrating the highest sensitivity and SPPB the highest specificity. Optimized cut-offs improved performance compared to standard thresholds (G8: 12.5 vs 14; SPPB: 8 vs 9; IF-VIG: 0.16 vs 0.25). Adjusted Cox models confirmed significant associations with 1-year mortality: hazard ratio [HR] 1.97 (95% CI 1.30-2.99) for G8, 2.35 (95% CI 1.52-3.64) for SPPB, and 2.42 (95% CI 1.50-3.90) for IF-VIG. CONCLUSIONS: All frailty tools were significantly associated with 1-year mortality. SPPB and IF-VIG outperformed G8 in prognostic accuracy, highlighting their potential utility in clinical decision-making for older patients with cancer.

来源:J Gerontol A Biol Sci Med Sci,查看原文。版权归原作者所有。

引用

  1. Ferrara MC, Zambom-Ferraresi F, Ribera A, et al. Predicting 1-year mortality in older cancer patients: performance of G8, SPPB, and IF-VIG in the PROFIT Study. J Gerontol A Biol Sci Med Sci. 2026. PMID: 41992809. doi:10.1093/gerona/glag099

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。